Ascophyllum Nodosum, Fucus Vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients

Giuseppe Derosa1–3
Maria Divina Pascuzzo4
Angela D’Angelo1,2
Pamela Maffioli1

1Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy; 3Center for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 4Ambulatory Center ASL Torino 4 and ASL Città Di Torino, Torino, Italy

Aim: To evaluate the actions of a combination of polyfenolic composition (extracted from Ascophyllum Nodosum and Fucus Vesiculosus, InSea2®) and chromium picolinate compared to placebo in addition to previously taken anti-diabetic therapy in patients with type 2 diabetes.

Methods: 175 Caucasian patients with type 2 diabetes were randomized to take nutraceutical combination or placebo for 6 months. One hundred and sixty-four cases completed the study. At baseline and after 6 months, glyco-metabolic control and lipid profile were evaluated.

Results: Glycated hemoglobin was significantly reduced by the nutraceutical combination, but not by placebo, both compared to baseline (p<0.05), and compared to placebo (p<0.05). A similar trend was recorded for fasting plasma glucose (FPG) [-23.5% (p=0.01) vs baseline, and -18.0% (p=0.01) vs placebo] and post-prandial glucose (PPG) [-17.1% (p<0.01) vs baseline, and -11.1% (p<0.05) vs placebo]. No variations of lipid profile were recorded compared to baseline, even if it seems to observe a reduction trend of triglycerides level in the nutraceutical group.

Conclusion: In conclusion, a nutraceutical combination of polyfenolic composition and chromium picolinate in addition to previously taken anti-diabetic therapy can be helpful in reducing glycated hemoglobin in patients with type 2 diabetes mellitus.

Keywords: Ascophyllum Nodosum, chromium, Fucus Vesiculosus, glycemic control

Introduction

In patients with type 2 diabetes mellitus, the correlation between cardiovascular complications and hyperglycemia is direct and linear. The impact of cardiovascular events is closely related to the worsening of glycemic control; this association appears even stronger when we consider post-prandial hyperglycemia.1 The post-prandial plasma glucose, in fact, has been shown to be an independent cardiovascular risk factor and a potent player in the induction of endothelial damage.2,3

An adequate lifestyle is the basis to obtain an adequate glycemic control, but to maintain an adequate lifestyle is not simple, especially if patient has a sedentary job. To help patients in following diet, in the latest years nutraceuticals have been marketed. Nutraceuticals include a series of molecules with a favorable effect on glycemia and insulin-resistance.4 Among nutraceuticals, a specific polyfenolic composition (extracted from Ascophyllum Nodosum and Fucus Vesiculosus in ration 95/5) and chromium picolinate seems to have a positive action on glycemia in dysglycemic
patients. The polifenolic composition is composed by florotannins, which act inhibiting \( \alpha \)-amylase, and \( \alpha \)-glucosidase with an important hypoglycemic action in vivo.\(^6\) In particular they act on post-prandial hyperglycemia, slowing carbohydrate absorption. At the dose of 250–500 mg, this nutraceutical composition induces levels from 25 to 50 times higher in intestinal fluids, compared to inhibiting concentration in vitro. Inhibition happens with a not competitive and reversible mechanism of action on enzymes degrading carbohydrates.\(^6\) The inhibiting action toward enzymatic activities, reversible and not competitive, seems to reduce, in animal models (rats), glycemia and insulinemia after the administration of amids and glucose.

In literature, a study by Paradise et al\(^7\) showed that Ascophyllum Nodosum and Fucus Vesiculosus improve insulin homeostasis in response to carbohydrate ingestion in nondiabetic men and women. On this basis, our study is aimed to evaluate the effects of a combination of polyphenolic composition (extracted from Ascophyllum Nodosum and Fucus Vesiculosus in ration 95/5, InSea2\(^8\)), and chromium picolinate (Gdue\(^8\) marketed by Aesculapius Farmaceutici) compared to placebo in addition to previously taken anti-diabetic therapy in patients with type 2 diabetes mellitus.

### Materials and methods

#### Study design

We conducted this multicenter, 6-months, double-blind, randomized, controlled, clinical trial at the Department of Internal Medicine and Therapeutics, University of Pavia (Pavia, Italy) and at Ambulatory Center ASL Torino 4 and ASL Città di Torino (Torino, Italy).

The study protocol was approved by both institutional review boards and was conducted in accordance with the 1994 Declaration of Helsinki, and its amendments and the Code of Good Clinical Practice.\(^8\) All patients had to provide written informed consent before being enrolled in this study after a full explanation of the procedures had been given.

#### Patients

We enrolled 175 Caucasian subjects with type 2 diabetes mellitus, aged >18 of either sex (Table 1) according to the ESC (European Society of Cardiology) and EASD (European Association for the Study of Diabetes) Guidelines criteria.\(^9\) To be enrolled, patients needed to take different anti-diabetic treatments at a stable dose form at least 3 months, with glycated hemoglobin (HbA\(_1c\)) level >6.5%, and in overweight (BMI \(\geq\) 25 and <30 Kg/m\(^2\)).

### Table 1 Concomitant diseases and medications during the study

<table>
<thead>
<tr>
<th>Nutraceutical group</th>
<th>Placebo group</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>89</td>
</tr>
<tr>
<td>Concomitant disease, n (%)</td>
<td>83 (93.3)</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>53 (63.9)</td>
</tr>
<tr>
<td>Combined dyslipidemia</td>
<td>26 (31.3)</td>
</tr>
<tr>
<td>Hypertriglyceridemia</td>
<td>4 (4.8)</td>
</tr>
<tr>
<td>Concurrent medications, n (%)</td>
<td>89 (100.0)</td>
</tr>
<tr>
<td>Statins</td>
<td>66 (74.2)</td>
</tr>
<tr>
<td>Ezetimibe</td>
<td>11 (12.4)</td>
</tr>
<tr>
<td>Fibrates</td>
<td>12 (13.5)</td>
</tr>
<tr>
<td>Omega-3</td>
<td>5 (5.6)</td>
</tr>
<tr>
<td>Hypoglycemic diet only</td>
<td>3 (3.4)</td>
</tr>
<tr>
<td>Metformin</td>
<td>72 (80.9)</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>15 (16.9)</td>
</tr>
<tr>
<td>Meglitinide derivates</td>
<td>2 (2.2)</td>
</tr>
<tr>
<td>Pioglitazone</td>
<td>6 (6.7)</td>
</tr>
<tr>
<td>DPP-4 inhibitors</td>
<td>13 (14.6)</td>
</tr>
<tr>
<td>GLP-1 agonists</td>
<td>15 (16.9)</td>
</tr>
<tr>
<td>( \alpha )-glucosidase inhibitors</td>
<td>3 (3.4)</td>
</tr>
<tr>
<td>Insulin</td>
<td>21 (23.6)</td>
</tr>
</tbody>
</table>

Note: Data are expressed as n (%).

Abbreviations: DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon like peptide-1.

Patients with previous ketoacidosis or unstable or rapidly progressive diabetic retinopathy, nephropathy or neuropathy were excluded. Impaired hepatic function (defined as plasma aminotransferase and/or gamma-glutamyltransferase level higher than the upper limit of normal [ULN] for age and sex), impaired renal function (defined as serum creatinine level higher than the ULN for age and sex) or severe anemia were considered exclusion criteria. Patients affected by serious cardiovascular disease (CVD) (eg, New York Heart Association class I-IV congestive heart failure or a history of myocardial infarction or stroke) or cerebrovascular conditions within 6 months before study enrolment also were excluded. We did not include pregnant or breastfeeding women or women of childbearing potential not taking adequate contraceptive precautions.

Investigators contacted suitable patients, identified from review of case notes and/or computerized clinic registers, in person or by phone.

### Diet and physical activity

At baseline, all patients were already following an adequate diet, and were encouraged to maintain their usual physical activity. The controlled-energy diet (\(\sim\) 600 kcal
daily deficit) followed NCEP-ATP III recommendations,\textsuperscript{10} 50% of calories derived from carbohydrates, 30% from fat (<7% saturated, up to 10% polyunsaturated and up to 20% monounsaturated) and 20% from proteins, with a maximum cholesterol content of 300 mg/d, and 35 g/d of fiber. Patients were followed by a dietitian and/or specialist physician.

Treatments
Patients were randomized to take placebo or a nutraceutical agent containing extracted from Ascophyllum Nodosum and Fucus Vesiculosus in a ratio of 95/5 (InSea\textsuperscript{2}\textsuperscript{®}) and Chromium Picolinate (Gdue\textsuperscript{®} marketed by Aesculapius Farmaceutici: Gdue\textsuperscript{®} is a formulation of InSea\textsuperscript{2}\textsuperscript{®} and chromium) in a 1:1 ratio, for 6 months, in a randomized, double-blind, placebo-controlled design. Placebo was composed by silicon dioxide, magnesium stearate, dicalcium phosphate and microcrystalline cellulose. Both nutraceutical and placebo were supplied as identical, opaque, tablets in coded bottles to ensure the blind status of the study. Simple randomization was granted using a drawing of envelopes containing randomization codes prepared by a statistician. Medication compliance was assessed by counting the number of pills returned at the time of specified clinic visits. All medications were provided free of charge.

Assessments
Before starting the study, we collected medical history, physical examination, vital signs (blood pressure and heart rate), a 12-lead electrocardiogram, measurements of height and body weight, calculation of body mass index (BMI), abdominal circumference (Abd. Cir.), assessment of fasting plasma glucose (FPG), post-prandial glucose (PPG), glycated hemoglobin (HbA\textsubscript{1c}), lipid profile. Anthropometric and metabolic parameters were evaluated at baseline, and after 6 months.

For a description of how the above parameters were assessed, see our previous study.\textsuperscript{11}

Statistical analysis
A sample of approximately 150 patients was needed to have a power of the study by 80%. The calculation was made by considering a 2-tailed \( t \) test for paired data with an alpha error of 5%. Mean and standard deviation (SD) values were used to summarize quantitative data. We conducted an intention-to-treat (ITT) analysis in patients receiving ≥1 dose of study medication, and the tolerability analysis in patients receiving ≥1 dose of trial medication after randomization. Shapiro-Wilk test was performed for testing the normality of data. The comparison of variables between the two groups was performed with the Student \( t \) test for independent data, while paired \( t \) test was used to compare values obtained before and after treatment administration. Statistical analysis of data was performed using the Statistical Package for Social Sciences software version 11.0 (SPSS Inc., Chicago, Illinois, USA). Data are presented as mean (SD).\textsuperscript{12} For all statistical analyses, we considered \( p<0.05 \) as statistically significant.

Results
One hundred and seventy-five were enrolled in the trial, 89 were randomized to the nutraceutical combination, 86 to placebo; of these, 164 completed the trial. Eleven patients (8 in the nutraceutical group and 3 with placebo) did not complete the trial and the reasons for premature withdrawal were lost to follow-up (3 patients), withdrawal of informed consent (5 patients) and not compliant with the treatment (3 patients). Concomitant diseases and medications of all the patients are listed in Table 1.

Anthropometric parameters
No variation of body weight and BMI were recorded; however, a significant reduction of WC was recorded in the nutraceutical group (\( p<0.05 \)), but not in placebo group, compared to baseline (Tables 2 and 3).

Glyco-metabolic control
Glycated hemoglobin was significantly reduced by the nutraceutical combination, but not by placebo, both compared to baseline (\( p<0.05 \)) and compared to placebo (\( p<0.05 \)). A similar trend was recorded for FPG and PPG; both were reduced by the nutraceutical combination compared to baseline (\( p<0.01 \)) and to placebo (\( p<0.01 \) for FPG, and \( p<0.05 \) for PPG) (Tables 2 and 3).

Lipid profile
No variations of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and triglycerides (Tg) were recorded compared to baseline, even if there is a slight, but not significant, reduction of Tg level in the nutraceutical group (Tables 2 and 3).

Discussion
De Martin et al\textsuperscript{13} already reported a reduction of circumferences and blood glucose with this nutraceutical
combination, according to our results. The reduction of glycemia observed in our study can be due to the inhibiting action of the polyphenolic composition toward enzymatic activities, in an acarbose-like mechanism. The ability of a phytocomplex obtained from these algae to inhibit both enzymes has already been reported by Roy et al., and lately by Gabbia et al. Gabbia showed that the administration of this extract in mice fed with a diet rich in fat is associated with a delay in carbohydrate digestion, but also with a decrease in its assimilation. Furthermore, Ascophyllum Nodosum and Fucus Vesiculosus contain polyunsaturated fatty acids (PUFAs) and the quantity is abundant, ranging from near 44% to 48% for the Ascophyllum Nodosum and Fucus Vesiculosus, respectively. Our group demonstrated that n-3 PUFAs [Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA)] were effective in reducing glycemia in patients affected by impaired fasting plasma glucose or impaired glucose tolerance and seem to be helpful to slow the development of type 2 diabetes mellitus. Also, Ascophyllum Nodosum and Fucus Vesiculosus contain only EPA represented from near 4% to 10% of the total fatty acids, but, however, it could have contributed to improve glycemic control.

Moreover, also chromium can play a role on glyco-metabolic improvement. Chromium is an essential trace element involved in the metabolism of carbohydrates, lipids and proteins. The recommended daily intake of chromium is 40 μg, but diet often does not provide minimum quantities, also because its bioavailability is low, less than 2%. Chromium is a necessary cofactor for many insulin functions, because it promotes the binding to its receptors in the striated muscle cells, adipocytes and hepatocytes and furthermore, promotes the phosphorylation of the receptors. These mechanisms contribute to the transport of glucose in the liver, muscle and adipose tissue to be used for energetic purposes, thereby improving glucose tolerance.

A recent meta-analysis of 15 controlled clinical trials in a total of 1690 patients showed the beneficial effects of integration of chromium in diabetic patients. The studies document that chromium reduces hyperglycemia, corrects insulinemia, reduces the need of oral hypoglycemic agent, reduces TC and TG and allows better control of body weight and fat mass. The authors of the meta-analysis concluded that the analyzed data support the safety and efficacy of chromium and in particular of chromium picolinate in the control of cholesterol and hyperglycemia in type 2 diabetic patients.

A study limitation is that, although the combination therapy showed a significant effect, we still cannot know which of the composition worked. Since the chromium picolinate is widely used in prevention and treatment of type 2 diabetes mellitus with confirmed efficiency, a group
treated with only polyphenolic extracts or chromium picolinate designed as the single factor control could have been helpful to clarify this point. Another limitation was that the majority of patients were under hypoglycemic drugs, and in particular under metformin; however, background therapy was not changed during the six months trial to avoid bias.

Conclusion
A nutraceutical combination of polyphenolic composition (extracted from Ascophyllum Nodosum and Fucus Vesiculosus in ration 95/5) and chromium picolinate in addition to previously taken anti-diabetic therapy can be helpful in reducing HbA1c in patients with type 2 diabetes mellitus.

Disclosure
The authors report no conflicts of interest in this work.

References